TxCell Share Price

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-0.37%-3.88%+19.75%+78.35% 5.74TCr
+1.63%+0.98%+3.83%+38.21% 4.76TCr
+0.50%+2.94%+345.86%+722.17% 4.43TCr
+3.05%-1.80%+29.79%+34.51% 4.25TCr
+1.00%-1.46%+4.97%+111.90% 4.07TCr
-0.54%+2.93%+9.31%+54.06% 3.1TCr
+1.56%+4.53%+31.34%+26.92% 2.85TCr
+0.76%-1.45%-7.15%-11.12% 2.43TCr
Average +1.15%-0.59%+54.12%+127.69% 4.34TCr
Weighted average by Cap. +1.52%-0.84%+58.31%+136.94%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock